seems like all other cmet candidates are atp competitive. In calls over the years Brian Swartz positions tiva non-atp competitive feature as an advantage (or that's what he seems to imply). any thoughts about this? advantage?
From "Biotech Values" websire:
"In simplified term, better selectivity allows the drug to be dosed higher, thus better efficacy without added toxicity, which will be more easily combinable with other drugs without the need to reduce the dosage. Tivantinib has shown it can be combined with other agents at its single agent MTD without additional toxicity.
As of cMET negative/low, I have discussed this many times, ARQL didn't do cMET IHC test during phase 2. They did after Roche MetMab ph2, and at that time, they didn't have all tissues from all patients for IHC. The number you cited was reported early this year from some patients in ph2 when MARQUEE enrollment was almost done"